grant
GPC2 CARs in neuroblastoma: Mechanisms of resistance and efficacy of next-generation constructs
Organization CHILDREN'S HOSP OF PHILADELPHIALocation PHILADELPHIA, UNITED STATESPosted 1 Apr 2024Deadline 31 Mar 2029
NIHUS FederalResearch GrantFY20260-11 years oldAddressAffinityAngiotensin Converting EnzymeAngiotensin I-Converting EnzymeAntibodiesAntigen ReceptorsAntigen TargetingAntigensBackBindingBioinformaticsBiologyCAR T cell therapyCAR T cellsCAR T therapyCAR modified T cellsCAR-TCAR-TsCD143 AntigensCancer TreatmentCancersCarboxycathepsinCell BodyCell Communication and SignalingCell SignalingCell secretionCell surfaceCellsCellular SecretionCessation of lifeChildChild YouthChildhood CancersChildren (0-21)Children's HospitalClinical DataClinical TrialsCombined Modality TherapyCytotoxic cellDataDeathDevelopmentDipeptidyl Peptidase ADiseaseDisorderDorsumDown-RegulationEarly-Stage Clinical TrialsEngineeringEnzyme InductionGlypicanGoalsHealthHumanIND FilingIND applicationIND packageIND submissionImmuneImmune mediated therapyImmunesImmunocompetentImmunologically Directed TherapyImmunologyImmunotherapeutic agentImmunotherapyIn VitroIn complete remissionInnate ImmunityInterdisciplinary ResearchInterdisciplinary StudyIntracellular Communication and SignalingInvestigational New Drug ApplicationK lymphocyteKininase AKininase IILaboratoriesLinkLytotoxicityMacrophageMalignant Childhood NeoplasmMalignant Childhood TumorMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant Pediatric NeoplasmMalignant Pediatric TumorMalignant TumorMalignant childhood cancerMediatingMediatorMedicalMiceMice MammalsMissionModern ManMolecular InteractionMultidisciplinary CollaborationMultidisciplinary ResearchMultimodal TherapyMultimodal TreatmentMurineMusMφNK CellsNational Institutes of HealthNative ImmunityNatural ImmunityNatural Killer CellsNeuroblastomaNon-Specific ImmunityNonspecific ImmunityNormal TissueNormal tissue morphologyOncogene ProductsOncogene ProteinsOncoproteinsOutcomePDX modelPatient derived xenograftPediatric HospitalsPeptidyl-Dipeptidase APhase 1 Clinical TrialsPhase I Clinical TrialsPhenotypePhiladelphiaPositionPositioning AttributeProcessPublic HealthPublishingR-Series Research ProjectsR01 MechanismR01 ProgramReceptor ProteinRelapseResearchResearch GrantsResearch Project GrantsResearch ProjectsResistanceRoleSafetySignal TransductionSignal Transduction SystemsSignalingSurvivorsT cells for CART-CellsT-LymphocyteTechnologyTestingTherapeuticTranslational Research EnterpriseTreatment FailureTumor CellTumor EscapeTumor Immune EscapeUnited States National Institutes of HealthUpregulationadaptive immunityanti-cancer immunotherapyanti-cancer therapyanticancer immunotherapybench bed sidebench bedsidebench to bed sidebench to bedsidebench to clinicbench to clinical practicebiological signal transductioncancer evasioncancer immune escapecancer immune evasioncancer immunotherapycancer in a childcancer in childrencancer therapycancer-directed therapychild with cancerchildhood malignancychimeric antigen T cell receptorchimeric antigen receptorchimeric antigen receptor (CAR) T cell therapychimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cell therapychimeric antigen receptor T cellschimeric antigen receptor T therapychimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellsclinical translationclinically translatableco-morbidco-morbiditycombatcombination therapycombined modality treatmentcombined treatmentcomorbiditycomplete responsecytotoxicitydensitydesigndesigningdevelopmentaldifferential expressiondifferentially expresseddisialogangliosidesevidence baseextracellular vesiclesfirst in manfirst-in-humanhigh riskimmune competentimmune drugsimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based cancer therapiesimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmuno therapyimmunogenimmunologic therapeuticsimmunological synapseimmunotherapeuticsimmunotherapy agentimmunotherapy for cancerimmunotherapy of cancerin vivoinnovateinnovationinnovativeinsightkidsmalignancymonosialogangliosidesmouse modelmulti-modal therapymulti-modal treatmentmurine modelneoplasm/cancerneoplastic cellneuroblastoma cellnew drug targetnew druggable targetnew pharmacotherapy targetnew therapeutic targetnew therapy targetnext generationnovel drug targetnovel druggable targetnovel pharmacotherapy targetnovel therapeutic targetnovel therapy targetoverexpressoverexpressionpatient derived xenograft modelpediatric cancerpediatric malignancyphase 1 trialphase I protocolphase I trialpre-clinical efficacypreclinical efficacypressurepreventpreventingreceptorresistance mechanismresistantresistant mechanismsialogangliosidessocial rolesynergismtherapy failurethymus derived lymphocytetranscriptional differencestranslation research enterprisetranslational oncologytranslational research programtreatment risktumortumor evasiontumor immune evasionvesicle releasevesicular releaseyoungster
Description preview
PROJECT SUMMARY
Children with high-risk neuroblastoma (NB) have a significant risk of treatment failure and death emphasizing
the need to develop novel targeted therapies, which constitutes the long-term goal of this proposal. The proposed
research focuses on the oncoprotein glypican-2 (GPC2), which is glycophosphatidylinositol (GPI)-linked to the…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click